Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.

Ellen Burgess Rajiv AgarwalStefan D AnkerGerasimos FilippatosBertram PittLuis M RuilopeVivian A Fonseca Guillermo E UmpierrezMaria Luiza CaramoriAmer JosephMarc LambeletRobert LawatscheckGeorge L Bakrisnull null

Published in: Diabetes, obesity & metabolism (2022)

The cardiorenal benefits of finerenone on composite cardiovascular and kidney outcomes and UACR reduction in patients with CKD and T2D appear to be maintained, regardless of GLP-1RA use. Subsequent studies are needed to investigate any potential benefit of this combination.

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
peritoneal dialysis
ejection fraction
newly diagnosed
rheumatoid arthritis
prognostic factors
cardiovascular disease
glycemic control
metabolic syndrome
risk assessment
adipose tissue
patient reported